Zenatane Capsule, Gelatin Coated
NDC Package 68001-652-17

11-digit billing NDC: 68001065217 · Billing unit: EA · 30 EA per package

Package Information

Zenatane (isotretinoin) capsules is severe Recalcitrant Nodular AcneZenatane is indicated for the treatment of severe recalcitrant nodular acne. This formulation utilizes a capsule, gelatin coated delivery system. Marketed by Bluepoint Laboratories, this product is identified by NDC 68001-652 and is authorized under FDA application ANDA202099.

Identification & Billing

NDC Package Code
68001-652-17
Package Description
3 BLISTER PACK in 1 CARTON / 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK (68001-652-16)
Product Code
11-Digit Billing Format
68001065217
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zenatane
Non-Proprietary Name
Isotretinoin
Substance Name
Isotretinoin
Dosage Form
Capsule, Gelatin Coated - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin; through a banding process, the capsule is coated with additional layers of gelatin so as to form a complete seal.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Severe Recalcitrant Nodular AcneZenatane is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, 2means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Zenatane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.In addition, Zenatane is indicated only for those patients who are not pregnant, because Zenatane can cause life threatening birth defects (see BoxedCONTRAINDICATIONSAND WARNINGS ).  A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients. 1,3,4If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off Zenatane. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis, Premature Epiphyseal Closure).

Regulatory & Marketing

Labeler Name
Bluepoint Laboratories
Product Type
Human Prescription Drug
FDA Application #
ANDA202099
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-30-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68001-652-17 identifies a specific commercial package of 3 blister pack in 1 carton / 10 capsule, gelatin coated in 1 blister pack (68001-652-16) of Zenatane, a human prescription drug labeled by Bluepoint Laboratories. This capsule, gelatin coated is formulated for oral use and contains isotretinoin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bluepoint Laboratories on December 30, 2025. The current certification is valid through December 31, 2027.

How is this Bluepoint Laboratories product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68001065217. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68001-652-17
11-Digit CMS (5-4-2)
68001-0652-17

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.